Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

About Alice Zhang

Alice Zhang is an angel investor.

Alice Zhang Headquarter Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Alice Zhang News

Eli Lilly taps Verge Genomics in ALS deal worth $25M upfront

Jul 8, 2021

Jul 8, 2021 6:30am Allying with Eli Lilly will allow Verge Genomics to explore earlier-stage targets and take “multiple shots on goal” with a leader in the neuro space, said Verge CEO and co-founder Alice Zhang. (Verge Genomics) As Verge Genomics plugs away at its amyotrophic lateral sclerosis (ALS) program, it is teaming up with Eli Lilly to pursue even more targets for new treatments against the devastating disease. The neuroscience-focused drug discoverer will pick up $25 million in an upfront fee, equity and near-term payments but stands to collect up to $694 million down the line. Under the three-year deal, Verge will use its artificial-intelligence-powered drug discovery platform to identify new targets of which Lilly may select up to four to push into clinical development and commercialization. The targets under the deal will not overlap with Verge’s in-house pipeline of treatments for ALS and other neurodegenerative ailments. “We have a wealth of compelling targets with strong genetic support … We picked two to focus on to develop to the clinic, but there are a number of promising targets that we don’t have the capacity to prosecute ourselves,” said Verge CEO and co-founder Alice Zhang. Allying with Lilly will allow Verge to explore some of those earlier-stage targets and take “multiple shots on goal” with a leader in the neuro space, she said. Verge plans to start clinical trials for its lead program, an ALS treatment that targets the enzyme PIKfyve, next year, Zhang said. And the company announced in June 2020 that it had partnered with an unnamed pharma company to screen its library of PIKfyve inhibitors for potential antiviral activity against SARS-CoV-2, the virus that causes COVID-19. Zhang started Verge in 2015 to remedy a major problem in drug discovery: translation. Although the industry has dramatically improved how efficiently it can screen and make new drugs, the cost of drug development has still grown exponentially because targets aren’t translating from animals to humans, she said.

Alice Zhang Investments

2 Investments

Alice Zhang has made 2 investments. Their latest investment was in Osmind as part of their Series A on July 7, 2021.

CBI Logo

Alice Zhang Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/1/2021

Series A

Osmind

$15M

No

5

10/14/2020

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/1/2021

10/14/2020

Round

Series A

Seed VC - II

Company

Osmind

Subscribe to see more

Amount

$15M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

5

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.